ストックスクリーナーアプリを入手
1.20
0.83%
-0.01
前日終値:
$1.21
開ける：
$1.2
24時間の取引高:
1.31M
Relative Volume:
0.41
時価総額：
$921.24M
収益：
$711.41M
当期純損益:
$-133.73M
株価収益率:
-6.3158
EPS:
-0.19
ネットキャッシュフロー:
$-199.99M
1週間 パフォーマンス:
-2.44%
1か月 パフォーマンス:
-6.98%
6か月 パフォーマンス:
-13.67%
1年 パフォーマンス:
-28.14%
1日の値動き範囲:
$1.19
$1.22
1週間の範囲:
$1.19
$1.24
52週間の値動き範囲:
$1.11
$2.035
Opko Health Inc Stock (OPK) Company Profile
Compare OPK vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.20 | 928.92M | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
510.93 | 193.53B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.50 | 149.33B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
635.66 | 50.36B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
122.90 | 35.73B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
333.33 | 32.24B | 3.17B | 642.63M | 539.81M | 10.77 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-20 | 開始されました | JP Morgan | Neutral |
| 2025-10-31 | ダウングレード | Jefferies | Buy → Hold |
| 2025-04-25 | 開始されました | JP Morgan | Neutral |
| 2023-06-29 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-24 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 開始されました | Ladenburg Thalmann | Buy |
| 2019-11-25 | 開始されました | Piper Jaffray | Overweight |
| 2018-03-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-09-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 繰り返されました | Standpoint Research | Buy |
| 2016-06-03 | 開始されました | Standpoint Research | Buy |
| 2016-03-31 | 繰り返されました | Barrington Research | Outperform |
| 2015-10-16 | 開始されました | JP Morgan | Overweight |
| 2015-09-11 | ダウングレード | Jefferies | Buy → Hold |
| 2015-03-03 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 繰り返されました | Oppenheimer | Outperform |
| 2014-03-14 | 開始されました | Oppenheimer | Outperform |
| 2013-11-13 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2013-05-30 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-10-22 | 開始されました | Barrington Research | Outperform |
| 2011-12-01 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2011-07-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Opko Health Inc (OPK) 最新ニュース
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? - The Globe and Mail
OPKO Health (OPK) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Finviz
Opko Health, Inc. (OPK) Investor Outlook: Unpacking The 189.30% Potential Upside - DirectorsTalk Interviews
11 Best High Return Penny Stocks to Buy Right Now - Insider Monkey
Esoteric Testing Market: Generated Opportunities and Future - openPR.com
Why OPKO Health Inc. stock is favored by top institutionsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
OPKO Health, Inc. to Announce 2025 Financial Results on February 26, 2026 - Quiver Quantitative
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - OPKO Health, Inc.
What is the long term forecast for OPKO Health Inc. stockWall Street Watch & AI Enhanced Trade Execution Alerts - mfd.ru
OPKO Health Insider Ups Holding During Year - Yahoo Finance
What hedge fund activity signals for OPKO Health Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Opko Health stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
OPKO Health, Inc. (OPK) Stock Analysis: Exploring A 191.67% Potential Upside - DirectorsTalk Interviews
Swing Trade: What is OPKO Health Incs 5 year growth outlookWeekly Risk Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development - Insider Monkey
11 Best Stocks Under $3 to Buy Right Now - Insider Monkey
OPKO and Entera expand collaboration to develop oral PTH treatment By Investing.com - Investing.com Nigeria
Opko Health and Entera Bio expand partnership to advance first-in-class oral long acting PTH tablet for patients with hypoparathyroidism - marketscreener.com
OPKO and Entera expand collaboration to develop oral PTH treatment - Investing.com
Entera Bio Expands OPKO Partnership, Adds New Director - TipRanks
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism - The Manila Times
Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism - TradingView
OPKO Health and Entera Bio expand partnership for oral PTH tablet - StreetInsider
Entera Bio Signs Amended And Restated Collaboration And License Agreement With OPKO - TradingView
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
OPKO Health and Entera Bio Expand Partnership to Advance - GlobeNewswire
Market Review: Is OPKO Health Inc likely to announce a buybackJuly 2025 Volume & Fast Entry High Yield Tips - baoquankhu1.vn
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts (NASDAQ:OPK) - Seeking Alpha
EV Market: Will OPKO Health Inc benefit from seasonality2025 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn
Analyst Calls: Does RAMP align with a passive investing strategyCPI Data & Low Risk Investment Opportunities - baoquankhu1.vn
OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of "Hold" from Analysts - MarketBeat
OPKO Health (NASDAQ:OPK) Stock Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Update Recap: What is OPKO Health Incs 5 year growth outlookJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Movement Recap: What drives Simulations Plus Incs stock priceQuarterly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Opko Health, Inc. (OPK) Stock Analysis: Exploring A Potential 177.99% Upside - DirectorsTalk Interviews
Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burg... - ADVFN
Options Flow: What is the long term forecast for OPKO Health Inc stockPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
OPKO Health (NASDAQ:OPK) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
OPK: Therapeutics-focused strategy, key partnerships, and innovative pipeline drive growth - TradingView — Track All Markets
Is OPKO Health (OPK) Pricing Reflect Its DCF Upside Despite Weak Long Term Returns - Yahoo Finance
Block Trades: Is OPKO Health Inc forming a double bottom2025 AllTime Highs & Accurate Buy Signal Notifications - baoquankhu1.vn
Assessing OPKO Health (OPK) Valuation After Diagnostics Refocus And Mixed Share Price Performance - Yahoo Finance
What are the future prospects of OPKO Health Inc.Exit Point & Smart Allocation Stock Tips - bollywoodhelpline.com
Opko Health, Inc. (OPK) Stock Analysis: Exploring A 167% Potential Upside For Investors - DirectorsTalk Interviews
Bearish Setup: Should I hold or sell OPKO Health Inc nowWeekly Stock Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Is OPKO Health Inc. stock undervalued vs historical averagesQuarterly Trade Summary & Low Risk Investment Opportunities - ulpravda.ru
Is OPKO Health Inc. stock vulnerable to regulatory risks2025 Dividend Review & Advanced Technical Analysis Signals - Улправда
Is OPKO Health Inc. stock supported by innovation pipelineShare Buyback & Real-Time Chart Pattern Alerts - Улправда
Why OPKO Health Inc. stock is considered a top pick2025 Fundamental Recap & Weekly Watchlist for Hot Stocks - Улправда
Opko Health Inc (OPK) 財務データ
収益
当期純利益
現金流量
EPS
Opko Health Inc (OPK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Aug 08 '25 |
Buy |
1.32 |
675,000 |
891,000 |
214,676,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 10 '25 |
Buy |
1.36 |
125,000 |
169,712 |
214,001,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
0.01%
0.07%
大文字化:
|
ボリューム (24 時間):